Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib as a second or third line EGFR-TKI
Latest Information Update: 16 Jul 2021
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 16 Jul 2021 New trial record